JP5205370B2 - シクロプロピル縮合インドロベンゾアゼピンhcvns5b阻害剤 - Google Patents
シクロプロピル縮合インドロベンゾアゼピンhcvns5b阻害剤 Download PDFInfo
- Publication number
- JP5205370B2 JP5205370B2 JP2009512305A JP2009512305A JP5205370B2 JP 5205370 B2 JP5205370 B2 JP 5205370B2 JP 2009512305 A JP2009512305 A JP 2009512305A JP 2009512305 A JP2009512305 A JP 2009512305A JP 5205370 B2 JP5205370 B2 JP 5205370B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- hcv
- compound
- cyclohexyl
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003112 inhibitor Substances 0.000 title claims 5
- JYGUARFTLQSWDG-UHFFFAOYSA-N 3,12-diazatetracyclo[9.7.0.02,8.013,18]octadeca-1,3,5,7,9,11,13,15,17-nonaene Chemical compound C1=CC=NC2=C3C4=CC=CC=C4N=C3C=CC2=C1 JYGUARFTLQSWDG-UHFFFAOYSA-N 0.000 title description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 110
- 239000000203 mixture Substances 0.000 claims abstract description 65
- -1 benzyloxy, amino Chemical group 0.000 claims description 93
- 125000000217 alkyl group Chemical group 0.000 claims description 67
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 24
- 229910052739 hydrogen Inorganic materials 0.000 claims description 22
- 239000001257 hydrogen Substances 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 17
- 125000003282 alkyl amino group Chemical group 0.000 claims description 16
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 16
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 14
- 108700008776 hepatitis C virus NS-5 Proteins 0.000 claims description 12
- 108010050904 Interferons Proteins 0.000 claims description 10
- 102000014150 Interferons Human genes 0.000 claims description 10
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 10
- 150000002431 hydrogen Chemical class 0.000 claims description 10
- 229940079322 interferon Drugs 0.000 claims description 10
- 125000001188 haloalkyl group Chemical group 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 125000002393 azetidinyl group Chemical group 0.000 claims description 8
- 125000002757 morpholinyl group Chemical group 0.000 claims description 8
- 125000003386 piperidinyl group Chemical group 0.000 claims description 8
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 8
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims description 8
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 7
- 108010036949 Cyclosporine Proteins 0.000 claims description 7
- 229960001265 ciclosporin Drugs 0.000 claims description 7
- 125000004193 piperazinyl group Chemical group 0.000 claims description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 229930182912 cyclosporin Natural products 0.000 claims description 5
- 108060004795 Methyltransferase Proteins 0.000 claims description 4
- 101800001019 Non-structural protein 4B Proteins 0.000 claims description 4
- 101800001014 Non-structural protein 5A Proteins 0.000 claims description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 3
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 2
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000004692 haloalkylcarbonyl group Chemical group 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 229940121649 protein inhibitor Drugs 0.000 claims 3
- 239000012268 protein inhibitor Substances 0.000 claims 3
- 229940122750 HCV entry inhibitor Drugs 0.000 claims 1
- 229940124683 HCV polymerase inhibitor Drugs 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 102000015696 Interleukins Human genes 0.000 claims 1
- 108010063738 Interleukins Proteins 0.000 claims 1
- 229940122055 Serine protease inhibitor Drugs 0.000 claims 1
- 101710102218 Serine protease inhibitor Proteins 0.000 claims 1
- 101000998548 Yersinia ruckeri Alkaline proteinase inhibitor Proteins 0.000 claims 1
- 208000010710 hepatitis C virus infection Diseases 0.000 claims 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 claims 1
- 239000003001 serine protease inhibitor Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 241000711549 Hepacivirus C Species 0.000 abstract description 64
- 238000000034 method Methods 0.000 abstract description 33
- 230000000694 effects Effects 0.000 abstract description 21
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 107
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 54
- OTDWHDOTZWWCFA-UHFFFAOYSA-N 12-azapentacyclo[10.7.0.02,7.08,10.013,18]nonadeca-1(19),2,4,6,8,10,13,15,17-nonaene-9-carboxamide Chemical compound C=1N2C3=CC=CC=C3C=C2C2=CC=CC=C2C2=C(C(=O)N)C2=1 OTDWHDOTZWWCFA-UHFFFAOYSA-N 0.000 description 52
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 46
- 230000002829 reductive effect Effects 0.000 description 44
- 239000000243 solution Substances 0.000 description 44
- 230000014759 maintenance of location Effects 0.000 description 43
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 41
- 239000000543 intermediate Substances 0.000 description 35
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 33
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 28
- 239000007787 solid Substances 0.000 description 27
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 25
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 22
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 239000012074 organic phase Substances 0.000 description 21
- SHYXRIAQMCXPAT-UHFFFAOYSA-N 12-azapentacyclo[10.7.0.02,7.08,10.013,18]nonadeca-1(19),2,4,6,8,10,13,15,17-nonaene-9-carboxylic acid Chemical compound C=1N2C3=CC=CC=C3C=C2C2=CC=CC=C2C2=C(C(=O)O)C2=1 SHYXRIAQMCXPAT-UHFFFAOYSA-N 0.000 description 18
- VSCBATMPTLKTOV-UHFFFAOYSA-N 2-tert-butylimino-n,n-diethyl-1,3-dimethyl-1,3,2$l^{5}-diazaphosphinan-2-amine Chemical compound CCN(CC)P1(=NC(C)(C)C)N(C)CCCN1C VSCBATMPTLKTOV-UHFFFAOYSA-N 0.000 description 16
- FRUWAONHRDGSAL-UHFFFAOYSA-N 7h-indolo[2,1-a][2]benzazepine-10-carboxylic acid Chemical compound C1=CCN2C3=CC(C(=O)O)=CC=C3C=C2C2=CC=CC=C21 FRUWAONHRDGSAL-UHFFFAOYSA-N 0.000 description 16
- 150000004702 methyl esters Chemical class 0.000 description 16
- 239000012071 phase Substances 0.000 description 16
- 238000002953 preparative HPLC Methods 0.000 description 16
- 230000002441 reversible effect Effects 0.000 description 16
- 238000003556 assay Methods 0.000 description 14
- 239000011734 sodium Substances 0.000 description 14
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 13
- 208000015181 infectious disease Diseases 0.000 description 12
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 12
- 235000019439 ethyl acetate Nutrition 0.000 description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 10
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 8
- 108010047761 Interferon-alpha Proteins 0.000 description 8
- 102000006992 Interferon-alpha Human genes 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- QMHAHUAQAJVBIW-UHFFFAOYSA-N [methyl(sulfamoyl)amino]methane Chemical compound CN(C)S(N)(=O)=O QMHAHUAQAJVBIW-UHFFFAOYSA-N 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- HJHICYAWGPPIND-UHFFFAOYSA-N 7h-indolo[2,1-a][2]benzazepine-10-carboxamide Chemical compound C1=CCN2C3=CC(C(=O)N)=CC=C3C=C2C2=CC=CC=C21 HJHICYAWGPPIND-UHFFFAOYSA-N 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 239000012141 concentrate Substances 0.000 description 7
- 235000008504 concentrate Nutrition 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000010898 silica gel chromatography Methods 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- QRKIDYBDEVJLFN-UHFFFAOYSA-N 5h-indolo[2,1-a][2]benzazepine-10-carboxamide Chemical compound C1C=CN2C3=CC(C(=O)N)=CC=C3C=C2C2=CC=CC=C21 QRKIDYBDEVJLFN-UHFFFAOYSA-N 0.000 description 6
- YWPFHRZMBHDGCX-UHFFFAOYSA-N 5h-indolo[2,1-a][2]benzazepine-10-carboxylic acid Chemical compound C1C=CN2C3=CC(C(=O)O)=CC=C3C=C2C2=CC=CC=C21 YWPFHRZMBHDGCX-UHFFFAOYSA-N 0.000 description 6
- 0 CN(CC1)CCN1S(C(C[n]1c2c3)=Cc(cc(cc4)OC)c4-c1c(C1CCCCC1)c2ccc3C(OC)=O)(=*)=O Chemical compound CN(CC1)CCN1S(C(C[n]1c2c3)=Cc(cc(cc4)OC)c4-c1c(C1CCCCC1)c2ccc3C(OC)=O)(=*)=O 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- 101710118046 RNA-directed RNA polymerase Proteins 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 229960000329 ribavirin Drugs 0.000 description 5
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 5
- 229910000104 sodium hydride Inorganic materials 0.000 description 5
- BPLKQGGAXWRFOE-UHFFFAOYSA-M trimethylsulfoxonium iodide Chemical compound [I-].C[S+](C)(C)=O BPLKQGGAXWRFOE-UHFFFAOYSA-M 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 229930105110 Cyclosporin A Natural products 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 4
- 238000001952 enzyme assay Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 208000006454 hepatitis Diseases 0.000 description 4
- 231100000283 hepatitis Toxicity 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 229910052763 palladium Inorganic materials 0.000 description 4
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- XQBDRIDNEPEVTF-UHFFFAOYSA-N 3-(cyclohexen-1-yl)-1h-indole-6-carboxylic acid Chemical compound C=1NC2=CC(C(=O)O)=CC=C2C=1C1=CCCCC1 XQBDRIDNEPEVTF-UHFFFAOYSA-N 0.000 description 3
- KSUSPFTZZVGBDT-UHFFFAOYSA-N 4-ethenylsulfonylmorpholine Chemical compound C=CS(=O)(=O)N1CCOCC1 KSUSPFTZZVGBDT-UHFFFAOYSA-N 0.000 description 3
- 108010006035 Metalloproteases Proteins 0.000 description 3
- 102000005741 Metalloproteases Human genes 0.000 description 3
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 3
- 101800001020 Non-structural protein 4A Proteins 0.000 description 3
- 101800001554 RNA-directed RNA polymerase Proteins 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- 108010022999 Serine Proteases Proteins 0.000 description 3
- 102000012479 Serine Proteases Human genes 0.000 description 3
- 101800001838 Serine protease/helicase NS3 Proteins 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 3
- ISGMYFROWQKXIL-UHFFFAOYSA-N methyl 3-cyclohexyl-1h-indole-6-carboxylate Chemical compound C=1NC2=CC(C(=O)OC)=CC=C2C=1C1CCCCC1 ISGMYFROWQKXIL-UHFFFAOYSA-N 0.000 description 3
- URJQGXVTZAIZAA-UHFFFAOYSA-N methyl 3-cyclohexyl-2-(2-formyl-4-methoxyphenyl)-1h-indole-6-carboxylate Chemical compound C=1C=C(OC)C=C(C=O)C=1C=1NC2=CC(C(=O)OC)=CC=C2C=1C1CCCCC1 URJQGXVTZAIZAA-UHFFFAOYSA-N 0.000 description 3
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 3
- 238000002165 resonance energy transfer Methods 0.000 description 3
- 125000000547 substituted alkyl group Chemical group 0.000 description 3
- DGUWACLYDSWXRZ-UHFFFAOYSA-N (2-formylphenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1C=O DGUWACLYDSWXRZ-UHFFFAOYSA-N 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 description 2
- NWWDDUXLUXVLIY-UHFFFAOYSA-N 1-ethenylsulfonyl-4-methylpiperazine Chemical compound CN1CCN(S(=O)(=O)C=C)CC1 NWWDDUXLUXVLIY-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- OZJSQVKDKOOQIT-UHFFFAOYSA-N 3-cyclohexyl-1h-indole-6-carboxylic acid Chemical compound C=1NC2=CC(C(=O)O)=CC=C2C=1C1CCCCC1 OZJSQVKDKOOQIT-UHFFFAOYSA-N 0.000 description 2
- 108020005544 Antisense RNA Proteins 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 2
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000710781 Flaviviridae Species 0.000 description 2
- 101710200424 Inosine-5'-monophosphate dehydrogenase Proteins 0.000 description 2
- 102100040018 Interferon alpha-2 Human genes 0.000 description 2
- 108010079944 Interferon-alpha2b Proteins 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 108010076039 Polyproteins Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 108700022715 Viral Proteases Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 2
- 229960003805 amantadine Drugs 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000011210 chromatographic step Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000003184 complementary RNA Substances 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 229960002751 imiquimod Drugs 0.000 description 2
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
- 239000002348 inosinate dehydrogenase inhibitor Substances 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 229940117681 interleukin-12 Drugs 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- QOQJFUQDXVNLMK-UHFFFAOYSA-N methyl 2-bromo-3-cyclohexyl-1h-indole-6-carboxylate Chemical compound BrC=1NC2=CC(C(=O)OC)=CC=C2C=1C1CCCCC1 QOQJFUQDXVNLMK-UHFFFAOYSA-N 0.000 description 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- JQRYUMGHOUYJFW-UHFFFAOYSA-N pyridine;trihydrobromide Chemical compound [Br-].[Br-].[Br-].C1=CC=[NH+]C=C1.C1=CC=[NH+]C=C1.C1=CC=[NH+]C=C1 JQRYUMGHOUYJFW-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229960000888 rimantadine Drugs 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- NVXWLLDJCHOIBZ-UHFFFAOYSA-N (2,3,4,5,6-pentafluorophenyl) ethenesulfonate Chemical compound FC1=C(F)C(F)=C(OS(=O)(=O)C=C)C(F)=C1F NVXWLLDJCHOIBZ-UHFFFAOYSA-N 0.000 description 1
- JXDNUMOTWHZSCB-XMTZKCFKSA-N (3s)-3-acetamido-4-[[(2s)-3-carboxy-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1r)-1-carboxy-2-sulfanylethyl]carbamoyl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound OC(=O)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(O)=O JXDNUMOTWHZSCB-XMTZKCFKSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- BJEWLOAZFAGNPE-UHFFFAOYSA-N 1-ethenylsulfonylethane Chemical compound CCS(=O)(=O)C=C BJEWLOAZFAGNPE-UHFFFAOYSA-N 0.000 description 1
- GHTDODSYDCPOCW-UHFFFAOYSA-N 1h-indole-6-carboxylic acid Chemical compound OC(=O)C1=CC=C2C=CNC2=C1 GHTDODSYDCPOCW-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- AGBXYHCHUYARJY-UHFFFAOYSA-N 2-phenylethenesulfonic acid Chemical compound OS(=O)(=O)C=CC1=CC=CC=C1 AGBXYHCHUYARJY-UHFFFAOYSA-N 0.000 description 1
- OQMSHITZFTVBHN-UHFFFAOYSA-N 3-methyl-3,8-diazabicyclo[3.2.1]octane Chemical compound C1N(C)CC2CCC1N2 OQMSHITZFTVBHN-UHFFFAOYSA-N 0.000 description 1
- WCKQPPQRFNHPRJ-UHFFFAOYSA-N 4-[[4-(dimethylamino)phenyl]diazenyl]benzoic acid Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(C(O)=O)C=C1 WCKQPPQRFNHPRJ-UHFFFAOYSA-N 0.000 description 1
- SJISCEAZUHNOMD-UHFFFAOYSA-N 4-phenylcyclohexan-1-amine Chemical compound C1CC(N)CCC1C1=CC=CC=C1 SJISCEAZUHNOMD-UHFFFAOYSA-N 0.000 description 1
- SJQRQOKXQKVJGJ-UHFFFAOYSA-N 5-(2-aminoethylamino)naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(NCCN)=CC=CC2=C1S(O)(=O)=O SJQRQOKXQKVJGJ-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- AMHUPTLRWMGEPK-UHFFFAOYSA-N CN(C)S(NC(c1ccc(c(C2CCCCC2)c-2[n]3CC(S(N4CCN(C)CC4)(=O)=O)=Cc4c-2ccc(OC)c4)c3c1)=O)(=O)=O Chemical compound CN(C)S(NC(c1ccc(c(C2CCCCC2)c-2[n]3CC(S(N4CCN(C)CC4)(=O)=O)=Cc4c-2ccc(OC)c4)c3c1)=O)(=O)=O AMHUPTLRWMGEPK-UHFFFAOYSA-N 0.000 description 1
- SMHDXMWRCFELTI-UHFFFAOYSA-N COC(c1ccc(c(C2CCCCC2)c(-c2c(C=O)cccc2)[nH]2)c2c1)=O Chemical compound COC(c1ccc(c(C2CCCCC2)c(-c2c(C=O)cccc2)[nH]2)c2c1)=O SMHDXMWRCFELTI-UHFFFAOYSA-N 0.000 description 1
- KHXCGJRWZOQDSY-UHFFFAOYSA-N COC(c1ccc(c(C2CCCCC2)c-2[n]3Cc4c-2cccc4)c3c1)=O Chemical compound COC(c1ccc(c(C2CCCCC2)c-2[n]3Cc4c-2cccc4)c3c1)=O KHXCGJRWZOQDSY-UHFFFAOYSA-N 0.000 description 1
- ZPILLRXEISXACZ-SEGJVHEOSA-N C[C@H](C1)N(C)[C@@H](C)CN1S(C(C1)(C[n]2c3c4)C1c(cc(cc1)OC)c1-c2c(C1CCCCC1)c3ccc4C(NS(N(C)C)(=O)=O)=O)(=O)=O Chemical compound C[C@H](C1)N(C)[C@@H](C)CN1S(C(C1)(C[n]2c3c4)C1c(cc(cc1)OC)c1-c2c(C1CCCCC1)c3ccc4C(NS(N(C)C)(=O)=O)=O)(=O)=O ZPILLRXEISXACZ-SEGJVHEOSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229940122604 HCV protease inhibitor Drugs 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010029660 Intrinsically Disordered Proteins Proteins 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 102000008021 Nucleoside-Triphosphatase Human genes 0.000 description 1
- 108010075285 Nucleoside-Triphosphatase Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108090000944 RNA Helicases Proteins 0.000 description 1
- 102000004409 RNA Helicases Human genes 0.000 description 1
- 108010052090 Renilla Luciferases Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- FZSWIHTVPYPOKW-UHFFFAOYSA-M [OH-].CC(CCC)[N+](CCCC)(CCCC)CCCC Chemical compound [OH-].CC(CCC)[N+](CCCC)(CCCC)CCCC FZSWIHTVPYPOKW-UHFFFAOYSA-M 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 150000003934 aromatic aldehydes Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- NJSUFZNXBBXAAC-UHFFFAOYSA-N ethanol;toluene Chemical compound CCO.CC1=CC=CC=C1 NJSUFZNXBBXAAC-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002374 hemiaminals Chemical class 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- AYYOZKHMSABVRP-UHFFFAOYSA-N methyl 1h-indole-6-carboxylate Chemical compound COC(=O)C1=CC=C2C=CNC2=C1 AYYOZKHMSABVRP-UHFFFAOYSA-N 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 125000005322 morpholin-1-yl group Chemical group 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical class NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 description 1
- 150000003456 sulfonamides Chemical group 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Description
本出願は、米国仮出願第60/808,331号(2006年5月25日出願)の利益を主張する。
1つの本発明の態様は式I:
R1はCO2R5またはCONR6R7であり;
R2はヒドロキシ、アルコキシ、ベンジルオキシ、アミノ、アルキルアミノ、ジアルキルアミノ、(アミノアルキル)アミノ、(アミノアルキル)(アルキル)アミノ、ジ(アミノアルキル)アミノ、((アルキルアミノ)アルキル)アミノ、((アルキルアミノ)アルキル)(アルキル)アミノ、ジ((アルキルアミノ)アルキル)アミノ、((ジアルキルアミノ)アルキル)アミノ、((ジアルキルアミノ)アルキル)(アルキル)アミノ、ジ((ジアルキルアミノ)アルキル)アミノ、((COR11)アルキル)アミノ、((COR11)アルキル)(アルキル)アミノ、アルキル、ハロアルキル、アミノアルキル、(アルキルアミノ)アルキル、(ジアルキルアミノ)アルキル、または(R12)アルキルであるか;
またはR2はアゼチジニル、ピロリジニル、ピペリジニル、ピペラジニル、モルホリニル、チオモルホリニル、ホモピペリジニル、ホモピペラジニル、またはホモモルホリニルであり、かつヒドロキシ、アミノ、アルキルアミノ、ジアルキルアミノ、アルキル、アルコキシアルキル、アミノアルキル、(アルキルアミノ)アルキル、(ジアルキルアミノ)アルキル、アルキルSO2、およびハロアルキルSO2からなる群から選択される0〜3個の置換基で置換されるか;
またはR2は
またはR2は1つの窒素を介して該SO2部分に結合する[4.3.0]または[3.3.0]二環式ジアミンであり、かつ0〜2個のR8置換基で置換され;
R3は水素、ハロ、アルキル、アルケニル、ヒドロキシ、ベンジルオキシ、アルコキシ、またはハロアルコキシであり;
R4はシクロアルキルであり;
R5は水素またはアルキルであり;
R6は水素、アルキル、アルキルSO2、シクロアルキルSO2、ハロアルキルSO2、(R9)2NSO2、または(R10)SO2であり;
R7は水素またはアルキルであり;
R8は水素、アルキル、シクロアルキル、(シクロアルキル)アルキル、アルキルカルボニル、シクロアルキルカルボニル、ハロアルキルカルボニル、アルコキシカルボニル、アルキルSO2、シクロアルキルSO2、ハロアルキルSO2、アミノカルボニル、(アルキルアミノ)カルボニル、(ジアルキルアミノ)カルボニル、ベンジル、ベンジルオキシカルボニル、またはピリジニルであり;
R9は水素、アルキル、またはシクロアルキルであり; および
R10はアゼチジニル、ピロリジニル、ピペリジニル、ピペラジニル、モルホリニル、チオモルホリニル、ホモピペリジニル、ホモピペラジニル、またはホモモルホリニルであり、かつ0〜3個のアルキル置換基で置換され;
R11はアゼチジニル、ピロリジニル、ピペリジニル、ピペラジニル、N-アルキルピペラジニル、モルホリニル、チオモルホリニル、ホモピペリジニル、ホモピペラジニル、N-アルキルホモピペラジニル、またはホモモルホリニルであり; および
R12はアゼチジニル、ピロリジニル、ピペリジニル、ピペラジニル、N-アルキルピペラジニル、モルホリニル、チオモルホリニル、ホモピペリジニル、ホモピペラジニル、N-アルキルホモピペラジニル、またはホモモルホリニルである]
の化合物またはその医薬的に許容される塩である。
該化合物は、下記の方法を含む当該技術分野において既知の方法によって調製しうる。いくつかの試薬および中間体は当該技術分野において既知である。他の試薬および中間体は、当該技術分野において既知の方法によって、入手可能な物質を用いて調製することができる。該化合物の合成を記載するために用いられる可変基(例えば番号付けされた「R」置換基)は、該化合物の調製方法を説明することのみを意図し、特許請求の範囲または明細書の他のセクションで使用される可変基と混同されない。
該化合物は下記のHCV RdRpアッセイで測定されたとおりHCV NS5Bに対する活性を示した。
HCVのNS5Bタンパク質をコード化するcDNA、遺伝子型1bは、pET21a発現ベクターにクローン化された。該タンパク質を、溶解性を高めるために18アミノ酸C末端切断で発現した。大腸菌コンピテント細胞株BL21(DE3)を、該タンパク質の発現に用いた。培養物が600nmで2.0の光学密度に達するまで、培養物を37℃で〜4時間培養した。該培養物を20℃に冷却し、1mM IPTGで誘導した。新たなアンピシリンを50μg/mlの最終濃度まで加え、細胞を終夜20℃で培養した。
HCV RdRp 遺伝子型1bアッセイを、96ウェルプレート(Costar 3912)中60μLの最終量で走査した。該アッセイバッファーは、20mM Hepes、pH 7.5、2.5mM KCl、2.5mM MgCl2、1mM DTT、1.6 U RNAse阻害剤(Promega N2515)、0.1 mg/ml BSA(Promega R3961)、および2%グリセロールから構成される。すべての化合物はDMSO中に連続的に希釈し(3倍)、アッセイ中のDMSOの最終濃度が2%になるように、更に水に希釈した。HCV RdRp遺伝子型1b酵素を、28nMの最終濃度で使用した。ポリAテンプレートを6nMで使用し、ビオチン標識されたオリゴ−dT12プライマーを180nMの最終濃度で用いた。テンプレートは市販品から入手した(Amersham 27-4110)。ビオチン標識されたプライマーはシグマゲノシス(Sigma Genosys)によって製造された。3H-UTPを0.6μCi(0.29μM、全UTP)で使用した。反応を酵素の添加により開始し、30℃で60分間インキュベートし、SPAビーズ(4μg/μl、Amersham RPNQ 0007)を含む50mM EDTA(25μL)を加えて停止した。プレートは、室温での1時間以上のインキュベート後、パッカード トップ カウント(Packard Top Count)NXTで読み取った。
改良酵素アッセイは本質的には、以下の点以外は標準的な酵素アッセイとして記載されているように実施した:プライマーとビーズをアッセイバッファー中混ぜて、室温で1時間インキュベートして、ビオチン標識されたオリゴdT12プライマーを、ストレプトアビジンで覆われたSPAビーズ上であらかじめ捕獲した。未結合のプライマーは、遠心分離後除去した。プライマー結合ビーズを20mM Hepesバッファー(pH 7.5)中に再懸濁し、20nMプライマーおよび0.67μg/μlビーズの最終濃度でのアッセイに用いた。アッセイにおける添加の順序:酵素(14nM)を希釈した化合物加え、続いてテンプレート(0.2nM)、3H-UTP(0.6μCi、0.29μM)、およびプライマー結合ビーズの混合物を添加して、反応を開始した(示した濃度は最終である)。反応は4時間30℃で続けた。
HCV FRETスクリーニングアッセイを行うために、96ウェル細胞培養プレートを用いた。FRETペプチド(アナスペック社)(Taliani et al., Anal. Biochem. 1996, 240, 60-67)は、ペプチドの一方の末端付近に蛍光ドナー、EDANS、もう一方の末端付近にアクセプター、DABCYLを含む。該ペプチドの蛍光発光をドナーとアクセプターとの間の分子間共鳴エネルギー転移(RET)でクエンチするが、NS3プロテアーゼが該ペプチドを切断するため、生成物はRETクエンチングから免れ、ドナーの蛍光は明らかとなる。アッセイ試薬は以下のようにして調製された。プロメガ(#E153A)から入手した5×の細胞ルシフェラーゼ細胞培養溶解試薬をdH2Oで1×まで希釈し、NaClを加えて最終濃度150mMにし、FRETペプチドを2mM原液から20μM最終濃度に希釈した。
上述の試験化合物(FRETアッセイプレパレーション)の添加に続いて、様々な回数でプレートを取り除き、アラマーブルー(Alamar Blue) 溶液(Trek Diagnostics、#00-100)を、細胞毒性の測定のようにウェル毎に加えた。サイトフロアー(Cytoflour)4000装置(PEバイオシステムズ)に読み込んだ後、次いでプレートをPBSですすぎ、ついで上記のFRETペプチドアッセイ試薬(FRETアッセイプレパレーション)をウェルあたり30μl添加して、FRETアッセイに用いた。該プレートを次いでサイトフロアー(Cytoflour) 4000装置中に置き、340 励起/490 発光、20サイクルで自動モードおよびキネティックモードでのプレート読み取りにセットした。典型的には、読み取り後のエンドポイント分析を用いてのノイズへのシグナルは、少なくとも3倍であった。あるいは、アラマーブルー(Alamar Blue)読み取り後、プレートをPBSですすぎ、フェノールレッドを含まないDMEM(高グルコース)50μlを加え、プレートを次いで、プロメガ(Promega) デュアル−グロ(Dual−Glo)ルシフェラーゼアッセイシステムを用いて、ルシフェラーゼアッセイに用いた。
該化合物はHCV NS5Bに対する活性を示し、HCVおよびHCV感染の治療に有用であり得る。従って、別の本発明の態様は、化合物またはその医薬的に許容される塩、および医薬的に許容される担体を含む組成物である。
他に特別の定めのない限り、以下の中間体および実施例における分析に基づくLCMSデータは、以下のカラムと条件を用いて得られた。停止時間: グラジエント時間+1分; 開始濃度: 特に断りのない限り0% B; 溶離液 A: 10mM NH4OAc含有5%CH3CN/95%H2O(カラムA); 0.1% TFA含有10%MeOH/90% H2O(カラムB); 溶離液B: 10mM NH4OAc含有95%CH3CN/5%H2O(カラムA); 0.1%TFA含有90%MeOH/10% H2O(カラムB); カラムA: Waters Xbridge C18 10μm 2.1 x 50 mm; カラムB: Phenomenex C18 10μm 3.0 x 50 mm。
Claims (13)
- 式I:
R1はCO2R5またはCONR6R7であり;
R2はヒドロキシ、アルコキシ、ベンジルオキシ、アミノ、アルキルアミノ、ジアルキルアミノ、(アミノアルキル)アミノ、(アミノアルキル)(アルキル)アミノ、ジ(アミノアルキル)アミノ、((アルキルアミノ)アルキル)アミノ、((アルキルアミノ)アルキル)(アルキル)アミノ、ジ((アルキルアミノ)アルキル)アミノ、((ジアルキルアミノ)アルキル)アミノ、((ジアルキルアミノ)アルキル)(アルキル)アミノ、ジ((ジアルキルアミノ)アルキル)アミノ、((COR11)アルキル)アミノ、((COR11)アルキル)(アルキル)アミノ、アルキル、ハロアルキル、アミノアルキル、(アルキルアミノ)アルキル、(ジアルキルアミノ)アルキル、または(R12)アルキルであるか;
またはR2はアゼチジニル、ピロリジニル、ピペリジニル、ピペラジニル、モルホリニル、チオモルホリニル、ホモピペリジニル、ホモピペラジニル、またはホモモルホリニルであり、かつヒドロキシ、アミノ、アルキルアミノ、ジアルキルアミノ、アルキル、アルコキシアルキル、アミノアルキル、(アルキルアミノ)アルキル、(ジアルキルアミノ)アルキル、アルキルSO2、およびハロアルキルSO2からなる群から選択される0〜3個の置換基で置換されるか;
またはR2は
またはR2は1つの窒素を介して該SO2部分に結合する[4.3.0]または[3.3.0]二環式ジアミンであり、かつ0〜2個のR8置換基で置換され;
R3は水素、ハロ、アルキル、アルケニル、ヒドロキシ、ベンジルオキシ、アルコキシ、またはハロアルコキシであり;
R4はシクロアルキルであり;
R5は水素またはアルキルであり;
R6は水素、アルキル、アルキルSO2、シクロアルキルSO2、ハロアルキルSO2、(R9)2NSO2、または(R10)SO2であり;
R7は水素またはアルキルであり;
R8は水素、アルキル、シクロアルキル、(シクロアルキル)アルキル、アルキルカルボニル、シクロアルキルカルボニル、ハロアルキルカルボニル、アルコキシカルボニル、アルキルSO2、シクロアルキルSO2、ハロアルキルSO2、アミノカルボニル、(アルキルアミノ)カルボニル、(ジアルキルアミノ)カルボニル、ベンジル、ベンジルオキシカルボニル、またはピリジニルであり;
R9は水素、アルキル、またはシクロアルキルであり;および
R10はアゼチジニル、ピロリジニル、ピペリジニル、ピペラジニル、モルホリニル、チオモルホリニル、ホモピペリジニル、ホモピペラジニル、またはホモモルホリニルであり、かつ0〜3個のアルキル置換基で置換され;
R11はアゼチジニル、ピロリジニル、ピペリジニル、ピペラジニル、N−アルキルピペラジニル、モルホリニル、チオモルホリニル、ホモピペリジニル、ホモピペラジニル、N−アルキルホモピペラジニル、またはホモモルホリニルであり;および
R12はアゼチジニル、ピロリジニル、ピペリジニル、ピペラジニル、N−アルキルピペラジニル、モルホリニル、チオモルホリニル、ホモピペリジニル、ホモピペラジニル、N−アルキルホモピペラジニル、またはホモモルホリニルである]
の化合物またはその医薬的に許容される塩。 - R1がCONR6R7であり;R6がアルキルSO2、シクロアルキルSO2、ハロアルキルSO2、(R9)2NSO2、または(R10)SO2であり;およびR7が水素である、請求項1に記載の化合物。
- R3が水素である、請求項1に記載の化合物。
- R3がメトキシである、請求項1に記載の化合物。
- R4がシクロヘキシルである、請求項1に記載の化合物。
- R6がアルキルSO2、(R9)2NSO2または(R10)SO2である、請求項1に記載の化合物。
- R8が水素、アルキル、アルキルSO2、またはベンジルである、請求項1に記載の化合物。
- 請求項1に記載の化合物またはその医薬的に許容される塩、および医薬的に許容される担体を含む組成物。
- HCVに対して治療的有用性を有する別の化合物の少なくとも1つをさらに含み、該化合物はインターフェロン、シクロスポリン、インターロイキン、HCVメタロプロテアーゼ阻害剤、HCVセリンプロテアーゼ阻害剤、HCVポリメラーゼ阻害剤、HCVヘリカーゼ阻害剤、HCV NS4Bタンパク質阻害剤、HCV侵入阻害剤、HCV組み立て阻害剤、HCV放出阻害剤、HCV NS5Aタンパク質阻害剤、HCV NS5Bタンパク質阻害剤、およびHCVレプリコン阻害剤からなる群から選択される、請求項11に記載の組成物。
- 請求項1に記載の化合物またはその医薬的に許容される塩、および医薬的に許容される担体を含む、C型肝炎感染を治療するための組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US80833106P | 2006-05-25 | 2006-05-25 | |
US60/808,331 | 2006-05-25 | ||
PCT/US2007/069660 WO2007140254A2 (en) | 2006-05-25 | 2007-05-24 | Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009538347A JP2009538347A (ja) | 2009-11-05 |
JP5205370B2 true JP5205370B2 (ja) | 2013-06-05 |
Family
ID=38617899
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009512305A Expired - Fee Related JP5205370B2 (ja) | 2006-05-25 | 2007-05-24 | シクロプロピル縮合インドロベンゾアゼピンhcvns5b阻害剤 |
Country Status (9)
Country | Link |
---|---|
US (1) | US7456167B2 (ja) |
EP (1) | EP2029606B1 (ja) |
JP (1) | JP5205370B2 (ja) |
CN (1) | CN101490054B (ja) |
AT (1) | ATE469155T1 (ja) |
DE (1) | DE602007006796D1 (ja) |
ES (1) | ES2343914T3 (ja) |
NO (1) | NO20084645L (ja) |
WO (1) | WO2007140254A2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011503229A (ja) * | 2007-11-20 | 2011-01-27 | ブリストル−マイヤーズ スクイブ カンパニー | シクロプロピル縮合インドロベンズアゼピンhcvns5b阻害剤 |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005049622A1 (ja) * | 2003-11-19 | 2005-06-02 | Japan Tobacco Inc. | 5-5員縮合複素環化合物及びそのhcvポリメラーゼ阻害剤としての用途 |
US20070049593A1 (en) * | 2004-02-24 | 2007-03-01 | Japan Tobacco Inc. | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor |
US7659263B2 (en) | 2004-11-12 | 2010-02-09 | Japan Tobacco Inc. | Thienopyrrole compound and use thereof as HCV polymerase inhibitor |
US7521443B2 (en) * | 2006-05-17 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
US7541351B2 (en) * | 2007-01-11 | 2009-06-02 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US7541352B2 (en) * | 2007-02-02 | 2009-06-02 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US7517872B2 (en) * | 2007-02-22 | 2009-04-14 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US7998951B2 (en) * | 2007-03-05 | 2011-08-16 | Bristol-Myers Squibb Company | HCV NS5B inhibitors |
US7547690B2 (en) * | 2007-03-14 | 2009-06-16 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
US7541353B2 (en) * | 2007-03-14 | 2009-06-02 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US7521444B2 (en) * | 2007-03-14 | 2009-04-21 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US7538102B2 (en) * | 2007-03-14 | 2009-05-26 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
US7538103B2 (en) * | 2007-03-15 | 2009-05-26 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
ES2381410T3 (es) | 2007-05-04 | 2012-05-28 | Vertex Pharmceuticals Incorporated | Terapia de combinación paa el tratamiento de infecciones por VHC |
US8143243B2 (en) * | 2007-08-09 | 2012-03-27 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US7652004B2 (en) * | 2007-08-09 | 2010-01-26 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US7642251B2 (en) * | 2007-08-09 | 2010-01-05 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US8124601B2 (en) | 2007-11-21 | 2012-02-28 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
US8129367B2 (en) * | 2007-11-21 | 2012-03-06 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
EP2234977A4 (en) | 2007-12-19 | 2011-04-13 | Boehringer Ingelheim Int | VIRAL POLYMERASE INHIBITORS |
KR20100126560A (ko) * | 2008-03-27 | 2010-12-01 | 브리스톨-마이어스 스큅 컴퍼니 | 피롤리딘 융합된 인돌로벤자디아제핀 hcv ns5b 억제제 |
WO2009120650A1 (en) | 2008-03-27 | 2009-10-01 | Bristol-Myers Squibb Company | Aromatic heterocyclic fused indolobenzadiazepine hcv ns5b inhibitors |
MX2010010061A (es) * | 2008-03-27 | 2010-09-30 | Bristol Myers Squibb Co | Compuestos para el tratamiento de hepatitis c. |
EP2268643B1 (en) * | 2008-03-27 | 2014-08-06 | Bristol-Myers Squibb Company | Dioxolane and dioxolanone fused indolobenzadiazepine hcv ns5b inhibitors |
US8133884B2 (en) * | 2008-05-06 | 2012-03-13 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
CA2748034A1 (en) | 2008-12-23 | 2010-07-01 | Pharmasset, Inc. | Purified 2'-deoxy'2'-fluoro-2'-c-methyl-nucleoside-phosphoramidate prodrugs for the treatment of viral infections |
CN102325783A (zh) | 2008-12-23 | 2012-01-18 | 法莫赛特股份有限公司 | 嘌呤核苷的合成 |
PA8855601A1 (es) | 2008-12-23 | 2010-07-27 | Forformidatos de nucleósidos | |
JP2012514605A (ja) | 2009-01-07 | 2012-06-28 | サイネクシス,インコーポレーテッド | Hcvおよびhiv感染の治療への使用におけるシクロスポリン誘導体 |
US8143244B2 (en) * | 2009-02-26 | 2012-03-27 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
TWI576352B (zh) | 2009-05-20 | 2017-04-01 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
SG184323A1 (en) | 2010-03-31 | 2012-11-29 | Gilead Pharmasett Llc | Stereoselective synthesis of phosphorus containing actives |
US8563530B2 (en) | 2010-03-31 | 2013-10-22 | Gilead Pharmassel LLC | Purine nucleoside phosphoramidate |
TW201136945A (en) | 2010-03-31 | 2011-11-01 | Pharmasset Inc | Purine nucleoside phosphoramidate |
CA2818853A1 (en) | 2010-11-30 | 2012-06-07 | Gilead Pharmasset Llc | 2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus |
CN103649079B (zh) | 2010-12-22 | 2016-11-16 | Abbvie公司 | 丙型肝炎抑制剂及其用途 |
MX354958B (es) | 2011-09-16 | 2018-03-27 | Gilead Pharmasset Llc | Metodos para el tratamiento de vhc. |
US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
PL2950786T3 (pl) | 2013-01-31 | 2020-05-18 | Gilead Pharmasset Llc | Formulacja skojarzona dwóch związków przeciwwirusowych |
PL3038601T3 (pl) | 2013-08-27 | 2020-08-24 | Gilead Pharmasset Llc | Formulacja złożona dwóch związków przeciwwirusowych |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1719773E (pt) * | 2004-02-24 | 2009-06-03 | Japan Tobacco Inc | Compostos heterotetracíclicos fundidos e a sua utilização como inibidores da polimerase do hcv |
US7153848B2 (en) * | 2004-08-09 | 2006-12-26 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
US7348425B2 (en) * | 2004-08-09 | 2008-03-25 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
DE502005002697D1 (de) | 2004-10-13 | 2008-03-13 | Merck Patent Gmbh | Als kinaseinhibitoren geeignete derivate des n,n'-diphenylharnstoffs |
MX2007004979A (es) * | 2004-10-26 | 2007-06-14 | Angeletti P Ist Richerche Bio | Derivados de indol tetraciclicos como agentes antiviricos. |
GB0518390D0 (en) | 2005-09-09 | 2005-10-19 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
US7399758B2 (en) * | 2005-09-12 | 2008-07-15 | Meanwell Nicholas A | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
US7473688B2 (en) * | 2005-09-13 | 2009-01-06 | Bristol-Myers Squibb Company | Indolobenzazepine HCV NS5B inhibitors |
US7456165B2 (en) * | 2006-02-08 | 2008-11-25 | Bristol-Myers Squibb Company | HCV NS5B inhibitors |
US7456166B2 (en) * | 2006-05-17 | 2008-11-25 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
-
2007
- 2007-05-24 EP EP07811934A patent/EP2029606B1/en active Active
- 2007-05-24 US US11/753,137 patent/US7456167B2/en active Active
- 2007-05-24 AT AT07811934T patent/ATE469155T1/de not_active IP Right Cessation
- 2007-05-24 ES ES07811934T patent/ES2343914T3/es active Active
- 2007-05-24 CN CN200780027545XA patent/CN101490054B/zh not_active Expired - Fee Related
- 2007-05-24 DE DE602007006796T patent/DE602007006796D1/de active Active
- 2007-05-24 JP JP2009512305A patent/JP5205370B2/ja not_active Expired - Fee Related
- 2007-05-24 WO PCT/US2007/069660 patent/WO2007140254A2/en active Application Filing
-
2008
- 2008-11-04 NO NO20084645A patent/NO20084645L/no not_active Application Discontinuation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011503229A (ja) * | 2007-11-20 | 2011-01-27 | ブリストル−マイヤーズ スクイブ カンパニー | シクロプロピル縮合インドロベンズアゼピンhcvns5b阻害剤 |
Also Published As
Publication number | Publication date |
---|---|
JP2009538347A (ja) | 2009-11-05 |
US7456167B2 (en) | 2008-11-25 |
EP2029606B1 (en) | 2010-05-26 |
EP2029606A2 (en) | 2009-03-04 |
NO20084645L (no) | 2008-12-19 |
WO2007140254A2 (en) | 2007-12-06 |
ES2343914T3 (es) | 2010-08-12 |
ATE469155T1 (de) | 2010-06-15 |
WO2007140254A3 (en) | 2008-01-24 |
CN101490054B (zh) | 2012-05-16 |
CN101490054A (zh) | 2009-07-22 |
US20070275947A1 (en) | 2007-11-29 |
DE602007006796D1 (de) | 2010-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5205370B2 (ja) | シクロプロピル縮合インドロベンゾアゼピンhcvns5b阻害剤 | |
JP5284952B2 (ja) | シクロプロピル縮合インドロベンゾアゼピンhcvns5b阻害剤 | |
US7521441B2 (en) | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors | |
JP5306230B2 (ja) | C型肝炎の治療用化合物 | |
JP5343011B2 (ja) | C型肝炎の治療のための化合物 | |
JP5416710B2 (ja) | シクロプロピル縮合インドロベンズアゼピンhcvns5b阻害剤 | |
JP5406837B2 (ja) | C型肝炎を治療するための四環系化合物 | |
JP5306366B2 (ja) | C型肝炎治療のための化合物 | |
WO2007140200A2 (en) | Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors | |
JP2010521483A (ja) | シクロプロピル縮合インドロベンゾアゼピンhcvインヒビター | |
WO2007143521A1 (en) | Cyclopropyl fused indolobenzazepine hcv inhibitors | |
WO2008103637A1 (en) | Compounds for the treatment of hepatitis c | |
JP2010521482A (ja) | C型肝炎の治療のための化合物 | |
WO2008109584A1 (en) | Hcv ns5b inhibitors | |
JP2011504178A (ja) | C型肝炎治療のための化合物 | |
EP2401280B1 (en) | Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors | |
JP2010518016A (ja) | C型肝炎治療のためのインドロベンズアゼピン誘導体 | |
JP2011515484A (ja) | ピロリジン縮合インドロベンザジアゼピンhcvns5b阻害剤 | |
KR20100134699A (ko) | 디옥솔란 및 디옥솔라논 융합된 인돌로벤자디아제핀 hcv ns5b 억제제 | |
AU2009228214B2 (en) | Dioxolane and dioxolanone fused indolobenzadiazepine HCV NS5B inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100311 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120821 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121116 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130205 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130218 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160222 Year of fee payment: 3 |
|
LAPS | Cancellation because of no payment of annual fees |